According to the American Diabetes Association, the prevalence of gastroparesis is approximately 5% in patients with type 1 diabetes and 1% in type 2 diabetes. Gastroparesis is also called delayed gastric emptying, which is a disorder of the digestive tract causing food to remain in the stomach for a longer period than average. Common medications given to manage the disease include antihistamines, and antibiotics among others. Several clinical trials are ongoing to develop innovative diabetic gastroparesis therapeutics to improve and manage the condition including prokinetic agents or antiemetic agents.
The Diabetic Gastroparesis Pipeline Report by Expert Market Research gives comprehensive insights into diabetic gastroparesis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic gastroparesis. The diabetic gastroparesis pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic gastroparesis.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing diabetic gastroparesis pipeline development activities related to diabetic gastroparesis are covered.
Diabetic gastroparesis is a digestive condition that affects how the stomach moves food into the intestines and leads to bloating, nausea, and heartburn. Gastroparesis is a disorder characterized by delayed gastric emptying due to damage to the vagus nerve. The disease is more prevalent in patients having type 1 diabetes than type 2 diabetes. It can be a result of long-term high blood sugar levels which damage the nerves responsible for stomach function. The disease is more common in females than males and is more likely to develop in people who have had surgery around the esophagus, small intestine, or stomach. Moreover, people who have had radiation therapy around the stomach or chest areas are more likely to develop gastroparesis. The symptoms of diabetic gastroparesis include vomiting, nausea, abdominal pain, acid reflux, abdominal bloating, and lack of appetite among others.
The treatment for diabetic gastroparesis varies and includes changing the dosage and timing of insulin, oral diabetic gastroparesis therapeutic drugs such as metoclopramide or erythromycin which stimulate the stomach muscles and avoiding drugs that cause delayed gastric emptying among others. Clinical trials for diabetic gastroparesis are focusing on several aspects including new diabetic gastroparesis drug candidates, such as the developments of prokinetic agents or antiemetic agents, and combinational therapies. Currently, a clinical trial is investigating the use of oral cannabidiol in the treatment of gastroparesis. The results reported improvement in symptoms as well. The increased number of drug clinical trials for diabetic gastroparesis has impacted the pipeline landscape significantly.
This section of the diabetic gastroparesis report covers the analysis of diabetic gastroparesis drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s diabetic gastroparesis therapeutic assessment covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s diabetic gastroparesis clinical assessment covers 50+ drug analyses based on the route of administration.
The diabetic gastroparesis report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for diabetic gastroparesis with 32 pipeline drugs in phase II.
The drug molecules categories covered under diabetic gastroparesis pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Vanda Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a neurokinin 1 receptor (NK-1R) antagonist in development for the treatment of gastroparesis. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic gastroparesis.
The EMR diabetic gastroparesis report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic gastroparesis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and diabetic gastroparesis therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming diabetic gastroparesis drug candidates.
The trial is designed to evaluate whether CIN-102 (deudomperidone) can help reduce the symptoms of diabetic gastroparesis in adult patients. The trial is sponsored by CinDome Pharma, Inc. and is currently under phase II.
The objective of the study is to evaluate the clinical safety and effectiveness of diabetic gastroparesis drug candidate Metoclopramide Nasal Spray compared to placebo for reducing the symptoms associated with diabetic gastroparesis in adult women. The trial is sponsored by Evoke Pharma and is currently under phase III.
Vanda Pharmaceuticals is developing the drug and is currently under phase III. The study is being conducted to evaluate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms associated with gastroparesis.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Diabetic Gastroparesis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic gastroparesis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic gastroparesis treatment market trends, regulatory environments, and potential growth opportunities within diabetic gastroparesis pipeline insights.
Global Diabetic Gastroparesis Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share